Gameto

🎙️ Live from the Nasdaq studio: Our CEO & Co-Founder Dr. Dina Radenkovic Turner joined Kristina Ayanian to share how Gameto is working to make IVF faster, and more accessible—and what’s next as we build the future of women’s health. Our lead product, Fertilo, uses iPSC-derived ovarian support cells to reduce the physical and emotional burden of IVF, shortening hormonal stimulation from two weeks of daily injections to just a few days. We’re proud to share that our Phase 3 clinical trial will soon be enrolling patients in the U.S.—a meaningful milestone in our mission to bring women a new standard of care. For too long, women’s health has been underfunded, underserved, and outdated. At Gameto, we’re working to change that—starting with fertility, and continuing across the entire reproductive journey to menopause and beyond. 🎥 Watch the full NASDAQ interview here: https://lnkd.in/eqMu7-uD Learn more about our Phase 3 study here: https://lnkd.in/edhsxa7Y #WomensHealth #FertilityCare #IVF #Innovation #Biotech #iPSC #StemCells #FemTech #FutureOfHealth

This past week, the Gameto team traveled to Australia to meet with our partners at IVF Australia and Virtus Health amidst the integration of our product Fertilo which is being spearheaded by Drs. Gavin Sacks and Cheryl Phua at IVFA Sydney. It was a pleasure to spend time with them and their teams and discuss Fertilo’s usage and implementation at IVFA in-depth. Throughout the trip, our team also had productive meetings with physicians and lab directors located around the country to discuss implementing Fertilo in their own clinics. If you are a clinic located in Australia interested in using Fertilo, please reach out through the contact form located on our website. Thank you to the IVFA and Virtus teams for the warm welcome! We are excited to keep working to keep bringing Fertilo to clinics around the globe. Sabrina Piechota, Gus Haddad, Tammie Roy Ph.D.

Clinic Spotlight: Gameto is proud to partner with Concebir - Centro de fertilidad in Peru to offer our product, Fertilo, to patients seeking reproductive care. Under the leadership of Luis Guzmán, PhD and Dra. Pamela Villanueva Zúñiga at Pranor, the world’s first baby conceived using Fertilo was born last year – a significant milestone in reproductive medicine. If you are a patient in Peru interested in learning more about Fertilo and its benefits, reach out to Pranor directly to determine if you are a fit.

Clinic Spotlight: Gameto is excited to be partnered with Grupo Procrearte in Buenos Aires, the first clinic in Argentina to be offering Fertilo to patients. If you are a patient in Argentina interested in learning more about Fertilo and its benefits, reach out to Procrearte directly to determine if you are a fit. Gaston Rey Valzacchi

Today marks the first day of the Pacific Coast Reproductive Society's 2025 Annual Meeting in Indian Wells, CA, where experts in reproductive medicine gather to share the latest advancements in the field. Gameto's Chief Medical Officer, Dr. Gus Haddad, will be attending, engaging with leaders and innovators to discuss the future of fertility care. If you're attending, we’d love to connect—see you there! #reproductivehealth #womenshealth #PCRS2025

Gameto’s Phase 3 Clinical Trial study site is now live and in start-up phase with our investigator sites. The study is termed Fertilo in Vitro Research Study and Trial (FIRST), as it is the first ever Phase 3 trial in the United States using iPSC-derived cells. FIRST will be conducted at 15 sites across the United States in women aged 18 to 35 years old who meet the listed inclusion criteria. Stay tuned as we announce our study sites shortly! Link to our study site: https://lnkd.in/edhsxa7Y

Dr. Dina Radenkovic Turner, our CEO & Co-founder, spoke with Pharmaceutical Executive and shared key insights on how to bridge the gap in women’s health innovation and how we can better incentivize R&D in this critical space. In this interview, Dina highlights the challenges and opportunities in advancing women's health, from the need for better research models to the importance of policy reform and funding. Gameto’s work in iPSC-derived fertility treatments, including our lead product, Fertilo, now in Phase III clinical trials in the US, is a prime example of how cutting-edge science can drive real change in women's health. Watch the full Pharmaceutical Executive interview with Dina here: https://lnkd.in/eTpnywNe

🎉 International Women’s Day was a great way to start #SXSW! The focus on #WomensHealth has taken the stage. It was awesome to hear from Dr. Dina Radenkovic Turner of Gameto and Kim Smith, FACHE of Health Evolve, alongside an incredible lineup of leaders on the urgency and momentum driving change in women’s healthcare today. Thank you, Jennifer Kite-Powell, creator & host of the Tiny Little Victories Podcast, for amplifying these important conversations and sharing the impact of leaders like Kim who is working to transform women’s #healthcare. And because every great conversation deserves something sweet, shoutout to Sarah Hamouda for bringing her amazing FIX Dessert Chocolatier from #Dubai to SXSW! 🍫✨ #IWD #WomensHealth #SXSW #SpiteTracking #FemTech #Innovation

Reflecting on #InternationalWomensDay, the Mirvie team was moved by the energy, conversations, and commitment to #womenshealth at SXSW. From highlighting breakthroughs in the field to dynamic discussions on the need to pivot in this ever-changing landscape to achieve success, there was no better way to honor this day alongside visionaries like Dina Radenkovic Turner, Olivia Walton and Chelsea M.R. Hirschhorn and discuss how we keep up the momentum to fill the gaps in women’s health. #pregnancyhealth #maternalhealth

This International Women’s Day, Gameto hosted a panel at #SXSW to discuss the future of women’s health. We discussed biotech, consumer healthcare, investment, and advocacy and shared insights on how technology is reshaping care and why advancing innovative solutions in women’s health is more important than ever. The panelists explored the many benefits of working in women’s health, including the vast white space for novel treatments, diagnostics, and consumer products, along with the increasing financial power of women. At the same time, they addressed key challenges—such as the lack of dedicated women’s health divisions in pharma, gaps in basic education, censorship and the absence of strong IPO precedents. The conversation focused on actionable takeaways to drive progress and ensure women’s health gets the attention and investment it deserves. Thank you to our panelists and everyone who joined us. Let’s keep the momentum going! Dina Radenkovic Turner, Chelsea Hirschhorn, Maneesh Jain, Olivia Walton, Frida, Mirvie, Ingeborg Investments